

Subject: October 15 LES Connecticut Chapter Meeting - Save the Date
From: "lesct" <les-ct@compass-grp.com>
Date: Wed, 23 Sep 2009 15:08:57 -0400
To: <les-ct@c18-ss-1-lb.cnet.com>



LES Connecticut Chapter Meeting

The Birth of Kolltan Pharmaceuticals

Perspectives from Founder and University Tech Transfer

Please save the date to join your colleagues in the Connecticut business development community on October 15, 2009 in New Haven for presentation on the deal between Kolltan Pharmaceuticals and Yale University.

Kolltan, founded early in 2009, is developing monoclonal antibody-based cancer therapeutics targeting receptor tyrosine kinases discovered at Yale.

Michael Schmertzler, CEO, Kolltan Pharmaceuticals, Inc., will moderate a panel with **Arthur G. Altschul, Jr.**, Co-Founder and Chairman of Board of Directors of Kolltan Pharmaceuticals, Inc., and **Jon Soderstrom**, PhD, Managing Director, Office of Cooperative Research, Yale University.

You will also have an opportunity to network with your colleagues.

Date

October 15, 2009

Time

6:30PM - 9:30PM

Location

Yale School of Management
Horchow Hall, GM Room
55 Hillhouse Avenue
New Haven, CT

Panel Discussion

Moderator

Michael Schmertzler, CEO, Kolltan Pharmaceuticals, Inc.

Michael Schmertzler joined Kolltan in 2008 and is the company's Chief Executive Officer. Mr. Schmertzler is also the chairman of the board of PTC Therapeutics, Inc., a director of Cytokinetics, Inc. and Segway Inc., chair of the Investment Committee of Credit Suisse First Boston Equity Partners, chair of the Board of the National Outdoor Leadership School and a trustee of Phillips Academy Andover. He has been an adjunct professor in the Yale School of Management since 1997 and a lecturer in the Yale University Department of Economics since 2005. Mr. Schmertzler has previously had senior responsibility for the management of

approximately \$5 billion of committed capital as co-head of Private Equity at Credit Suisse First Boston in the United States and president of the Morgan Stanley Private Equity Funds. He has also served as a managing director in Morgan Stanley's Mergers and Acquisitions Department and as founder of that firm's biotechnology investment banking practice and as manager of its worldwide investment banking insurance practice. Prior to joining Morgan Stanley, Mr. Schmertzler served as head of International Investment Banking and Sales and Trading, chief financial officer, chief administrative officer as well as managing director of Lehman Brothers Kuhn Loeb and its successor company. Mr. Schmertzler was previously a member of the executive committee and a governor of the New York Academy of Sciences. Mr. Schmertzler holds a B.A. in city planning, history and molecular biophysics and biochemistry from Yale College; attended the Woodrow Wilson School at Princeton University; and has an M.B.A. from Harvard Business School.

Panelists

Arthur G. Altschul, Jr., Co-Founder and Chairman of Board of Directors of Kolltan Pharmaceuticals, Inc.

Mr. Altschul has worked in money management, investment banking and as a member of senior management of a publicly-traded health care concern. He is a founder of Diaz & Altschul Capital Management, LLC, a private investment advisory firm. Between 1985 and 1991, Mr. Altschul worked, variously, at Goldman, Sachs & Co., The Maximus Fund, LP and Morgan Stanley & Co. From its founding in 1992 through 1996, Mr. Altschul worked at SUGEN, Inc., a biopharmaceutical company focused on cancer drug development, which was subsequently acquired by Pharmacia & Upjohn, Inc. Mr. Altschul is chairman of the board of directors of Medrium, Inc., a leader in medical transaction processing; he serves on the board of directors of General American Investors, Inc. (NYSE: GAM), a publicly-traded closed-end investment company with over \$1 billion in gross assets and Medicis Pharmaceutical Corporation (NYSE: MRX), a specialty pharmaceutical company focused on the dermatology market. He also is a director of the Delta Opportunity Fund, Ltd., and Diversified Natural Products, Inc. Mr. Altschul is a director of The Overbrook Foundation, and is a trustee of The Neurosciences Research Foundation, and the National Public Radio Foundation. Mr. Altschul received his B.Sc. in Computer Science from Columbia University.

Jon Soderstrom, PhD, Managing Director, Office of Cooperative Research, Yale University

Dr. Soderstrom, a member of Kolltan's Board of Directors, is currently the Managing Director of the Office of Cooperative Research at Yale University. The Office manages the intellectual assets created at Yale to achieve the maximum benefit for the public and provide a financial return to support the University's research efforts. He is responsible for (1) developing and managing the intellectual property portfolio, (2) defining and executing commercialization strategies including negotiation of licenses and corporate-sponsored research agreements, and (3) development and marketing of business concepts for new spin-off ventures to the investment community. Since joining the Office in 1996, he has participated in the formation of more than 25 new ventures including polyGenomics, Molecular Staging (acquired by Qiagen), Agilix, Asilas Genomic Systems, Achillion Pharmaceuticals (NASQ: ACHN), PhytoCeutica, Protometrix (acquired by Invitrogen), Iconic Therapeutics, Applied Spine Technologies, HistoRx, VaxInnate and Affomix. Collectively, these companies have raised over \$350 million in professional venture capital. Prior to this position, Dr. Soderstrom was the Director of Program Development for Oak Ridge National Laboratory (ORNL) after serving for ten years as Director of Technology Licensing for Martin Marietta Energy Systems. In the Office of Technology Transfer, he directed a group of ten professionals responsible for negotiating licenses and Cooperative Research and Development Agreements (CRADAs).

Dr. Soderstrom was a founding board member and past president of the Association of Federal Technology Transfer Executives as well as a member of the Licensing Executive Society and Association of University Technology Managers where he is the 2008 President, has served as Vice President for Public Policy and a

member of the Board of Directors and Executive Committee. He is frequently asked to lecture and teach seminars on various aspects of the technology transfer process and economic development both within the United States and abroad. He has testified before Congress on technology transfer issues and served as an expert witness in patent infringement litigation. In addition to his professional accomplishments, Dr. Soderstrom was honored as the 87th "Point of Light" by President George H. W. Bush in March of 1990 for his volunteer activities helping to construct and rehabilitate low-income housing in East Tennessee. Dr. Soderstrom received his Ph.D. from Northwestern University in 1980 and his B.A. from Hope College in 1976.